HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Contemporary Characterization and Recategorization of Adult Unclassified Renal Cell Carcinoma.

Abstract
Our recent study of early-onset unclassified eosinophilic renal cell carcinoma (RCC) demonstrated that two third of cases could be reclassified by performing a limited number of immunohistochemistry stains. Following the same approach, we aimed to investigate what proportion of adult unclassified RCC could be reclassified. We identified 79 cases. The mean age at presentation was 58 years (range, 29 to 84 y). Tumors were grouped based on their predominant morphologic features as oncocytic (n=23); papillary (n=22); clear cell (n=22); mucinous tubular and spindle cell (MTSC; n=5); rhabdoid (n=4); or lacking a dominant pattern (n=3). By reviewing the morphologic features and performing ancillary studies, we were able to reclassify 10 cases (13%). Four cases were positive for CK20 and showed morphologic features consistent with eosinophilic solid and cystic RCC. Four cases were reclassified as MTSC based on VSTM2A expression by RNA in situ hybridization. One case was negative for SDHB and reclassified as succinate dehydrogenase-deficient RCC. None of the cases showed loss of expression of fumarate hydratase. One case was diffusely positive for CK7 and negative for CD117 and reclassified as a low-grade oncocytic tumor. Four cases were positive for both cathepsin-K and TFE3 by immunohistochemistry, although fluorescence in situ hybridization failed to identify rearrangement in either TFE3 or TFEB genes. Of the tumors that remained unclassified, those with oncocytic features were less likely to be a high grade (odds ratio [OR]=0.22, P=0.013) or advanced stage (OR=0.19, P=0.039) and were more common in women (OR=3.4, P=0.05) compared with those without oncocytic features. Tumors with rhabdoid morphology were associated with advanced stage (relative risk=3.6, P=0.009), while tumors with clear cell or papillary features had a wide range of grades and stages at presentation. In summary, the most frequent reclassified entity is eosinophilic solid and cystic RCC. Investigation of expression of succinate dehydrogenase or fumarate hydratase in individuals older than 35 years with unclassifiable tumors is low yield in the absence of specific morphologic features. A subset of MTSC without well-developed morphologic features can be reclassified by using RNA-ISH for VSTM2A. Recognition of more-recently described RCC subtypes allows for their distinction from the unclassified subtype and improves the prognostic information provided.
AuthorsRegina Kwon, Pedram Argani, Jonathan I Epstein, Kara A Lombardo, Xiaoming Wang, Phillip M Pierorazio, Rohit Mehra, Andres Matoso
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 45 Issue 4 Pg. 450-462 (04 01 2021) ISSN: 1532-0979 [Electronic] United States
PMID33239504 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Membrane Proteins
  • VSTM2A protein, human
  • Succinate Dehydrogenase
  • Fumarate Hydratase
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor (analysis, genetics)
  • Carcinoma, Renal Cell (chemistry, classification, genetics, pathology)
  • Databases, Factual
  • Female
  • Fumarate Hydratase (analysis)
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization, Fluorescence
  • Kidney Neoplasms (chemistry, classification, genetics, pathology)
  • Male
  • Membrane Proteins (genetics)
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Staging
  • Retrospective Studies
  • Succinate Dehydrogenase (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: